Search Results - "Little, J.M"

Dopamine as Rescue Therapy for Refractory Protein-Losing Enteropathy in Fontan-Palliated Patients by Friedland-Little, J.M, Gajarski, R.J, Schumacher, K.R

Get full text

The Impact of Ischemic Time on Early Rejection After Pediatric Heart Transplant by Magdo, H.S, Friedland-Little, J.M, Yu, S, Gajarski, R.J, Schumacher, K.S

Get full text

Outcomes of Third Heart Transplants in Pediatric and Young Adult Patients by Friedland-Little, J.M, Gajarski, R.J, Yu, S, Donohue, J.E, Zamberlan, M, Schumacher, K.R

“…Purpose Repeat heart transplantation (re-HTx) is standard practice in many pediatric centers, with acceptable outcomes in appropriate patients (pts). There are…”
Get full text

Lymphoproliferative Disorders Late After Pediatric Heart Transplantation: A Multicenter Analysis by West, S.C, Friedland-Little, J.M, Schowengerdt, K, Naftel, D, Pruitt, E, Smith, K.S, Urschel, S, Michaels, M, Kirklin, J.K, Feingold, B

Get full text

(1337) - Dapagliflozin Use in Children with Heart Failure Undergoing Heart Transplantation by Newland, D.M., Law, Y.M., Albers, E.L., Ali, R., Friedland-Little, J.M., Kemna, M.S., Knorr, L.R., Nemeth, T.L., Spencer, K.L., Hong, B.J.

Get full text

Safety of Dapagliflozin in Children with Heart Failure by Newland, D.M., Hong, B.J., Albers, E.L., Friedland-Little, J.M., Kemna, M.S., Law, Y.M.

“…Dapagliflozin recently received FDA-approval for use in adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and…”
Get full text

Analysis of Platelet Function Testing in Children Receiving Aspirin for Antiplatelet Effects by Newland, D.M., Palmer, M.M., Ahmed, H., Albers, E.L., Friedland-Little, J.M., Hong, B.J., Law, Y.M., Spencer, K.L., Kemna, M.S.

“…VerifyNow Aspirin assay (VN) assesses platelet response to ASA, with therapeutic effect defined as ≤ 549 aspirin reaction units (ARU). We aim to evaluate its…”
Get full text

(329) Mycophenolic Acid Therapeutic Drug Monitoring Using Area Under the Curve in Pediatric Heart Transplant Recipients by Newland, D.M., Pak, J.L., Ali, R., Nemeth, T.L., Tressel, W., Kronmal, R., Albers, E.L., Friedland-Little, J.M., Ahmed, H., Kemna, M.S., Hong, B.J., Spencer, K.L., Law, Y.M.

“…Pharmacokinetics (PK) of mycophenolic acid (MPA) display substantial interpatient variability, with up to 10-fold difference of exposure in individual patients…”
Get full text

(330) Prevalence of Iron Deficiency and Anemia in Pediatric Heart Transplant Recipients by Newland, D.M., Spencer, K.L., Do, L.D., Palmer, M.M., Ahmed, H., Albers, E.L., Friedland-Little, J.M., Hong, B.J., Kemna, M.S., Knorr, L.R., Mark, D., Schauer, J.S., Law, Y.M.

“…Prevalence of iron deficiency and anemia in the setting of modern-day maintenance immunosuppression in pediatric heart transplant (HTx) recipients is unclear…”
Get full text

Prevalence and Risk Factors of Proteinuria in Pediatric Heart Transplantation by Frandsen, E.L., Hingorani, S., Jorgensen, N., Albers, E.L., Friedland-Little, J.M., Kemna, M.S., Hong, B.J., Law, Y.M.

“…Renal dysfunction is a common complication of heart transplantation (HTx) in children, with consequent long term morbidity and mortality. Proteinuria reflects…”
Get full text

Antibody Mediated Rejection in Pediatric Heart Transplant Recipients by Frandsen, E.L., Gimferrer, I., Rudzinski, E.R., Ahmed, H., Albers, E.A., Friedland-Little, J.M., Hong, B.J., Kemna, M.S., Newland, D.M., Law, Y.M.

“…Pediatric heart transplant recipients who experience antibody mediated rejection (AMR) are at increased risk for poor graft outcomes. We report the incidence,…”
Get full text

Characteristics and Outcomes of Patients Supported with Impella Percutaneous VAD Device at Pediatric Institutions: Action Collaborative Experience by Tume, S.C., Shugh, S., Gillespie, M., Jeewa, A., Lorts, A., Joong, A., Friedland-Little, J.M., Lantz, J., Amdani, S.M., Butts, R., Burstein, D., Tannous, P., Rosenthal, D.N., Parent, J.J., Maurich, A., Oelkers, B., Wilkens, S.J., Esch, J.J., Law, S.P., Ghbeis, M., Torres, A.J., Fynn-Thompson, F., Hsu, D.T., Bansal, N., Qureshi, A., Adachi, I., Morray, B.

“…We describe Advanced Cardiac Therapies Improving Outcomes Network (ACTION) pediatric multicenter experience with Impella® percutaneous ventricular assist…”
Get full text

(1285) - Quality of Life in Children and Young Adults With Pulmonary Hypertension and Its Association With Clinical Features by Chau, P., Schumacher, K.R., Uzark, K., Grifka, R.G., Miller, C., Yu, S., Lowery, R., Friedland-Little, J.M.

Get full text

Implantable Cardioverter Defibrillator Use in Males with Duchenne Muscular Dystrophy and Severe Left Ventricular Dysfunction by McCulloch, M.A., Knecht, K.R., Butts, R.J., Villa, C.R., Johnson, J.N., Conway, J., Bock, M.J., Lal, A.K., Schumacher, K.R., Law, S.P., Friedland-Little, J.M., Desphande, S.R., West, S.C., Lytrivi, I.D., Gambetta, K.E., Wittlieb-Weber, C.A.

“…Duchenne muscular dystrophy (DMD) is characterized by myocardial fibrosis and left ventricular (LV) dysfunction. Implantable cardioverter defibrillator (ICD)…”
Get full text

Electrocardiographic Trends in Boys with Duchenne Muscular Dystrophy by Gambetta, K., Wittlieb-Weber, C.W., Villa, C.R., Conway, J., Johnson, J.N., Bock, M.J., Lal, A.K., Schumacher, K.R., Law, S.P., Deshpande, S., West, S.C., Friedland-Little, J.M., Lytrivi, I.D., Butts, R.J., Knecht, K.J., Michael, M.A.

“…Little is known about sudden cardiac death risk and arrhythmias in boys with Duchenne muscular dystrophy(DMD). The goal of the study is to describe ECG…”
Get full text

Risk Factors for Cardiac Causes of Death in Males with Duchenne Muscular Dystrophy by Wittlieb-Weber, C.A., Knecht, K.K., Villa, C.R., Cunningham, C., Bock, M.J., Gambetta, K.E., Lal, A.K., Schumacher, K.R., Law, S.P., Deshpande, S.R., West, S.C., Friedland-Little, J.M., Lytrivi, I.D., McCulloch, M.A., Butts, R.J., Weber, D.R., Johnson, J.N.

“…As survival and neuromuscular function in Duchenne Muscular Dystrophy (DMD) have improved with glucocorticoid therapy and advances in respiratory care, the…”
Get full text

Utilization of Heart Failure Medications in Duchenne Muscular Dystrophy Patients with Left Ventricular Systolic Dysfunction by Lal, A.K., Wittlieb-Weber, C.A., Villa, C.R., Cunningham, C., Bock, M.J., Gambetta, K.E., Johnson, J.N., Schumacher, K.R., Law, S.P., Deshpande, S.R., West, S.C., Friedland-Little, J.M., Lytrivi, I.D., McCulloch, M.A., Ou, Z., Presson, A.P., Butts, R.J.

“…Current guidelines for the management of left ventricular systolic dysfunction (LVSD) in Duchenne Muscular Dystrophy (DMD) recommend angiotensin converting…”
Get full text

The Role of Prophylactic Heart Failure Therapy in Duchenne Muscular Dystrophy by Lal, A.K., Wittlieb-Weber, C.A., Villa, C.R., Conway, J., Bock, M.J., Gambetta, K.E., Schumacher, K.R., Law, S.P., Deshpande, S.R., West, S.C., Friedland-Little, J.M., Lytrivi, I.D., McCulloch, M.A., Butts, R.J., Knecht, K.R., Ou, Z., Presson, A.P., Johnson, J.N.

“…There is variable practice and debate surrounding prophylactic heart failure (HF) therapy in Duchenne Muscular Dystrophy (DMD) patients with normal systolic…”
Get full text

Prevalence and Risk Factors of Proteinuria in Pediatric Heart Transplantation by Frandsen, E.L., Hingorani, S.R., Jorgensen, N., Albers, E.L., Friedland-Little, J.M., Kemna, M.S., Hong, B.J., Law, Y.M.

“…Renal dysfunction is a common complication of heart transplantation (HTx) in children that affects overall outcome. Proteinuria reflects renal glomerular and…”
Get full text

(993) - Use of Advanced Heart Failure Therapies in Duchenne Muscular Dystrophy by Wittlieb-Weber, C.A., Villa, C.R., Conway, J., Bock, M.J., Gambetta, K.E., Johnson, J.N., Lal, A.K., Schumacher, K.R., Law, S.P., Deshpande, S.R., West, S.C., Friedland-Little, J.M., Lytrivi, I.D., McCulloch, M.A., Butts, R.J., Weber, D.R., Knecht, K.R.

Get full text